国民保健制度批准联合王国开发的针对白血病复发成人的CAR T细胞疗法,该疗法可提供高的中转率和较少的副作用。 The NHS approves UK-developed CAR T-cell therapy for adults with relapsed leukemia, offering high remission rates and fewer side effects.

英格兰的国民保健制度批准了Aobe-cel(Auatzyl),这是由英国的Autolus开发的下一代CAR T细胞疗法,对象是26岁和26岁以上患有复发或复发性B细胞急性淋巴菌白血病的成年人。 The NHS in England has approved obe-cel (Aucatzyl), a next-generation CAR T-cell therapy developed by UK-based Autolus, for adults aged 26 and over with relapsed or refractory B-cell acute lymphoblastic leukaemia. 这种治疗在专科中心两次静脉注射中只需要一次终生剂量,相隔10天进行两次静脉注射,在对94名病人的试验中显示77%的恢复率,3年半后还剩下一半没有癌症。 The treatment, requiring only one lifetime dose in two intravenous infusions 10 days apart at specialist centres, showed 77% remission rates in a trial of 94 patients, with over half remaining cancer-free after three and a half years. 它提供的副作用比标准疗法少,有可能减少住院人数和改善生活质量。 It offers fewer side effects than standard therapies, potentially reducing hospital stays and improving quality of life. 预计在今后三年里,这项治疗将惠及150多名病人,标志着血液癌护理取得重大进步,得到老挝联合劳工联盟、老挝联合劳工联盟、政府和工业界合作的支持。 The therapy is expected to benefit more than 150 patients in the next three years and marks a major advancement in blood cancer care, backed by collaboration between UCL, UCLH, government, and industry. 病人和卫生官员都称赞这是医学创新方面的一个突破。 Patients and health officials have praised it as a breakthrough in medical innovation.